Product Information
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB is a generic product labeled by Taro Pharmaceuticals U.S.A. Inc., priced at $0.1699 per EA under NDC 51672404501. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Sep 18, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 12.5 mg/1; mg/1
Manufacturer
Taro Pharmaceuticals U.S.A. Inc.NDC
51672404501
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075788FDA Approved
9/18/2001
TE Code
AB
On Market Since
9/18/2001
Pharmacological Classes
Price Statistics
The NADAC for ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 144.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1699 per EA |
|---|---|
| All-time high | $0.2756 (Feb 12, 2020) |
| All-time low | $0.0695 (Nov 28, 2013) |
| 52-week high | $0.1973 |
| 52-week low | $0.1588 |
| Median price | $0.1562 |
| Average price | $0.1592 |
| Largest weekly change | +100.8% (Nov 19, 2014) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Enalapril Maleate and Hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Taro Pharmaceuticals U.S.A. Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Enalapril Maleate and Hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB, manufactured by Taro Pharmaceuticals U.S.A. Inc., is $0.1699 per EA (NDC 51672404501), effective Sep 30, 2026.
How has the price of ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB changed over time?
Over the history we have for it, the NADAC for ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB has risen 144.6%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB?
Since Nov 28, 2013, the NADAC for ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB has ranged from a low of $0.0695 (Nov 28, 2013) to a high of $0.2756 (Feb 12, 2020), with a median of $0.1562 per EA.
Are there cheaper alternatives to ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB?
ENALAPRIL-HYDROCHLOROTHIAZIDE 5-12.5 MG TAB (NDC 51672404501) is labeled by Taro Pharmaceuticals U.S.A. Inc., and CMS classifies it as a generic product.